CAR工程化NK细胞与CAR T细胞治疗胶质母细胞瘤的优劣对比
本文综述了CAR T细胞与CAR工程化NK细胞治疗胶质母细胞瘤(GBM)的进展,涵盖CAR导入方法、制造挑战及临床前与早期临床研究证据,并系统评估两类疗法的优势与不足,以探寻GBM的最佳免疫治疗策略。
要点
- CAR T细胞疗效受GBM靶抗原下调限制,CAR NK细胞具现货型异体产品优势且无GVHD风险。
- CAR NK细胞除CAR特异性外还有抗癌活性,可能降低复发或耐药风险。
- CAR T细胞已在临床广泛研究,而CAR修饰NK细胞治疗GBM大多仍处于临床前阶段。
核心结论
- CAR工程化NK细胞与CAR T细胞各有优势与不足,需综合评估以确定GBM的最佳治疗策略。
研究设计与样本
- 综述,讨论NK细胞与CAR T细胞治疗GBM的最新进展,包括CAR导入方法、制造挑战及临床前与早期临床研究证据。
主要发现
- CAR T细胞疗效受GBM靶抗原下调阻碍。
- CAR NK细胞面临类似挑战,但具现货型异体产品优势,无GVHD风险,且有超越CAR特异性的抗癌活性,可能降低复发或耐药风险。
- CAR T细胞疗法已在临床广泛研究,CAR修饰NK细胞治疗GBM大多仍处于临床前阶段。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glioblastoma (GBM) is a highly aggressive primary brain tumor that carries a grim prognosis. Because of the dearth of treatment options available for treatment of GBM, Chimeric Antigen Receptor (CAR)-engineered T cell and Natural Killer (NK) therapy could provide alternative strategies to address the challenges in GBM treatment. In these approaches, CAR T and NK cells are engineered for cancer-specific immunotherapy by recognizing surface antigens independently of major histocompatibility complex (MHC) molecules. However, the efficacy of CAR T cells is hindered by GBM's downregulation of its targeted antigens. CAR NK cells face similar challenges, but, in contrast, they offer advantages as off-the-shelf allogeneic products, devoid of graft-versus-host disease (GVHD) risk as well as anti-cancer activity beyond CAR specificity, potentially reducing the risk of relapse or resistance. Despite CAR T cell therapies being extensively studied in clinical settings, the use of CAR-modified NK cells in GBM treatment remains largely in the preclinical stage. This review aims to discuss recent advancements in NK cell and CAR T cell therapies for GBM, including methods for introducing CARs into both NK cells and T cells, addressing manufacturing challenges, and providing evidence supporting the efficacy of these approaches from preclinical and early-phase clinical studies. The comprehensive evaluation of CAR-engineered NK cells and CAR T cells seeks to identify the optimal therapeutic approach for GBM, contributing to the development of effective immunotherapies for this devastating disease.
引用
- Sabahi M, Fathi Jouzdani A, Sadeghian Z, et al. CAR-engineered NK cells versus CAR T cells in treatment of glioblastoma; strength and flaws. J Neurooncol. 2024. PMID: 39538038. doi:10.1007/s11060-024-04876-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。